219 related articles for article (PubMed ID: 31926212)
1. Stromal PD-1
Chen L; Cao MF; Xiao JF; Ma QH; Zhang H; Cai RL; Miao JY; Wang WY; Zhang H; Luo M; Ping YF; Yao XH; Cui YH; Zhang X; Bian XW
Hum Pathol; 2020 Mar; 97():68-79. PubMed ID: 31926212
[TBL] [Abstract][Full Text] [Related]
2. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
3. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.
Zhang Y; Du W; Chen Z; Xiang C
Exp Cell Res; 2017 Oct; 359(2):449-457. PubMed ID: 28830685
[TBL] [Abstract][Full Text] [Related]
5. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
[TBL] [Abstract][Full Text] [Related]
6. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma.
Sun J; Guo H; Nie Y; Zhou S; Zeng Y; Sun Y
Sci Rep; 2024 Apr; 14(1):9276. PubMed ID: 38653742
[TBL] [Abstract][Full Text] [Related]
8. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung.
Hirai A; Yoneda K; Shimajiri S; Kuroda K; Hanagiri T; Fujino Y; Tanaka F
J Thorac Cardiovasc Surg; 2018 Jan; 155(1):382-392.e1. PubMed ID: 28711324
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
Sumitomo R; Hirai T; Fujita M; Murakami H; Otake Y; Huang CL
Lung Cancer; 2019 Oct; 136():136-144. PubMed ID: 31499335
[TBL] [Abstract][Full Text] [Related]
14. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
15. Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
Nakamura H; Ichikawa T; Nakasone S; Miyoshi T; Sugano M; Kojima M; Fujii S; Ochiai A; Kuwata T; Aokage K; Suzuki K; Tsuboi M; Ishii G
Lung Cancer; 2018 Jan; 115():56-63. PubMed ID: 29290263
[TBL] [Abstract][Full Text] [Related]
16. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer.
Yagi T; Baba Y; Okadome K; Kiyozumi Y; Hiyoshi Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
Eur J Cancer; 2019 Apr; 111():38-49. PubMed ID: 30822683
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
18. Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma.
Zheng X; Weigert A; Reu S; Guenther S; Mansouri S; Bassaly B; Gattenlöhner S; Grimminger F; Pullamsetti S; Seeger W; Winter H; Savai R
Cancer Res; 2020 Oct; 80(20):4414-4425. PubMed ID: 32699134
[TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
20. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
